- Home
- STN vs EXEL Comparison
STN vs EXEL Comparison
Compare STN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STN
- EXEL
- Stock Information
- Founded
- STN 1954
- EXEL 1994
- Country
- STN Canada
- EXEL United States
- Employees
- STN N/A
- EXEL N/A
- Industry
- STN Military/Government/Technical
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STN Consumer Discretionary
- EXEL Health Care
- Exchange
- STN Nasdaq
- EXEL Nasdaq
- Market Cap
- STN 9.2B
- EXEL 9.7B
- IPO Year
- STN N/A
- EXEL 2000
- Fundamental
- Price
- STN $82.36
- EXEL $34.45
- Analyst Decision
- STN
- EXEL Buy
- Analyst Count
- STN 0
- EXEL 18
- Target Price
- STN N/A
- EXEL $31.72
- AVG Volume (30 Days)
- STN 121.4K
- EXEL 2.6M
- Earning Date
- STN 11-07-2024
- EXEL 10-29-2024
- Dividend Yield
- STN 0.76%
- EXEL N/A
- EPS Growth
- STN 6.58
- EXEL 441.02
- EPS
- STN 2.27
- EXEL 1.55
- Revenue
- STN $4,167,733,814.00
- EXEL $2,081,598,000.00
- Revenue This Year
- STN $16.06
- EXEL $20.53
- Revenue Next Year
- STN $9.34
- EXEL $1.54
- P/E Ratio
- STN $36.42
- EXEL $22.26
- Revenue Growth
- STN 13.64
- EXEL 17.31
- 52 Week Low
- STN $67.54
- EXEL $19.20
- 52 Week High
- STN $88.42
- EXEL $36.60
- Technical
- Relative Strength Index (RSI)
- STN 49.57
- EXEL 67.10
- Support Level
- STN $81.60
- EXEL $27.86
- Resistance Level
- STN $83.59
- EXEL $36.49
- Average True Range (ATR)
- STN 1.48
- EXEL 0.98
- MACD
- STN -0.06
- EXEL -0.01
- Stochastic Oscillator
- STN 37.15
- EXEL 74.10
About STN Stantec Inc
Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. The company is geographically diversified in three regional operating units namely Canada, United States and Global, offering similar services across all regions. The company offers services in various sectors across the project life cycle through five business operating units infrastructure, water, buildings, environmental services, and energy and resources. The company provides professional services in all phases of the project life cycle: planning, design, construction administration, commissioning, maintenance, decommissioning, and remediation.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.